Comparison · NCT03485950-deaths
Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: deaths from any cause. Trial comparisons, record NCT03485950-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03485950-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0638 | 0.0219 | 0.172 | wilson | |
| Risk in group 2 | 0.04 | 0.011 | 0.135 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0238 | -0.0796 | 0.135 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.6 | 0.279 | 9.13 | log | |
| Odds ratio, group 1 over group 2 | 1.64 | 0.261 | 10.3 | log | |
| Number needed to harm, for one more death from any cause on Ceftolozane/Tazobactam Arm than on Standard of Care (SOC) Arm | 42 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: standard of care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ceftolozane/Tazobactam Arm | Received IV Ceftolozane/Tazobactam (minimum of 9 doses). Patients may receive other additional therapy. | 3 | 47 | EG000 |
| Group 2 | Standard of Care (SOC) Arm | Received one of the following IV therapies: Cefepime (minimum of 9 doses), Meropenem (minimum of 9 doses), Piperacillin/Tazobactam (minimum of 12 doses). Patients may receive other additional therapy. | 2 | 50 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
From the date of the first dose of IV study drug to 30 days following the last dose of study drug. All patients were followed until last follow up which occurred 35-42 days following the first dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
- NCT number
- NCT03485950
- Phases
- PHASE2
- Conditions
- Other Infectious Diseases
- Interventions
- Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
- Lead sponsor
- M.D. Anderson Cancer Center
- Results first posted
- 2021-07-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03485950?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03485950-deaths